Mersana Therapeutics Net Worth
Mersana Therapeutics Net Worth Breakdown | MRSN |
Mersana Therapeutics Net Worth Analysis
Mersana Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Mersana Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Mersana Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Mersana Therapeutics' net worth analysis. One common approach is to calculate Mersana Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Mersana Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Mersana Therapeutics' net worth. This approach calculates the present value of Mersana Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Mersana Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Mersana Therapeutics' net worth. This involves comparing Mersana Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Mersana Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Mersana Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mersana Therapeutics' net worth research are outlined below:
| Mersana Therapeutics is way too risky over 90 days horizon | |
| Mersana Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 36.85 M. Net Loss for the year was (171.67 M) with loss before overhead, payroll, taxes, and interest of (146.8 M). | |
| Mersana Therapeutics currently holds about 225.13 M in cash with (168.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Mersana Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 95.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Citigroup Begins Coverage on Mersana Therapeutics |
Mersana Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mersana Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mersana Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Mersana Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mersana Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mersana Therapeutics backward and forwards among themselves. Mersana Therapeutics' institutional investor refers to the entity that pools money to purchase Mersana Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Schonfeld Strategic Advisors Llc | 2024-09-30 | 2.2 M | Goldman Sachs Group Inc | 2024-09-30 | 2 M | Boxer Capital Llc | 2024-09-30 | 1.8 M | Silverarc Capital Management, Llc | 2024-09-30 | 1.6 M | Deutsche Bank Ag | 2024-06-30 | 1.6 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.4 M | 5am Venture Management, Llc | 2024-09-30 | 1.3 M | Verition Fund Managegment, Llc | 2024-09-30 | 1.3 M | Longwood Capital Partners Llc | 2024-09-30 | 1.2 M | Ecor1 Capital, Llc | 2024-09-30 | 19.4 M | Nextech Invest Ag | 2024-09-30 | 12.1 M |
Follow Mersana Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 284.13 M.Market Cap |
|
Project Mersana Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.76) | (0.80) | |
| Return On Capital Employed | (1.05) | (1.11) | |
| Return On Assets | (0.76) | (0.80) | |
| Return On Equity | (4.65) | (4.42) |
When accessing Mersana Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Mersana Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mersana Therapeutics' profitability and make more informed investment decisions.
Evaluate Mersana Therapeutics' management efficiency
Mersana Therapeutics has return on total asset (ROA) of (0.263) % which means that it has lost $0.263 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.1333) %, meaning that it created substantial loss on money invested by shareholders. Mersana Therapeutics' management efficiency ratios could be used to measure how well Mersana Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 3rd of December 2024, Return On Tangible Assets is likely to drop to -0.8. In addition to that, Return On Capital Employed is likely to drop to -1.11. At this time, Mersana Therapeutics' Other Current Assets are very stable compared to the past year. As of the 3rd of December 2024, Fixed Asset Turnover is likely to grow to 5.34, while Total Assets are likely to drop about 180.4 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.32 | 0.30 | |
| Tangible Book Value Per Share | 0.32 | 0.30 | |
| Enterprise Value Over EBITDA | (0.77) | (0.81) | |
| Price Book Value Ratio | 7.30 | 7.66 | |
| Enterprise Value Multiple | (0.77) | (0.81) | |
| Price Fair Value | 7.30 | 7.66 | |
| Enterprise Value | 128.7 M | 122.2 M |
Leadership at Mersana Therapeutics emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Enterprise Value Revenue 4.606 | Revenue 34.8 M | Quarterly Revenue Growth 0.637 | Revenue Per Share 0.286 | Return On Equity (2.13) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mersana Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mersana Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mersana Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mersana Therapeutics Corporate Filings
F3 | 15th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 29th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Mersana Therapeutics Earnings per Share Projection vs Actual
Mersana Therapeutics Corporate Management
| Chuck Miller | Senior Affairs | Profile | |
| Carla Poulson | Chief Officer | Profile | |
| Marc Damelin | Oncology, Biology | Profile | |
| Jason Fredette | Senior Communications | Profile | |
| Mohan Bala | Senior Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mersana Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. To learn how to invest in Mersana Stock, please use our How to Invest in Mersana Therapeutics guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mersana Therapeutics. If investors know Mersana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mersana Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.60) | Revenue Per Share 0.286 | Quarterly Revenue Growth 0.637 | Return On Assets (0.26) | Return On Equity (2.13) |
The market value of Mersana Therapeutics is measured differently than its book value, which is the value of Mersana that is recorded on the company's balance sheet. Investors also form their own opinion of Mersana Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mersana Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mersana Therapeutics' market value can be influenced by many factors that don't directly affect Mersana Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mersana Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mersana Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mersana Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.